Hemab Therapeutics Holdings, Inc. Common Stock
COAG
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.1B
$44.41
▲ +0.09%
P/E
-33.90
Mkt Cap
$2.1B
52-Wk Range
$23.00–$55.42
52-Week Range
$23.00 - $55.42
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 30.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bispecific and monovalent antibody platform technology
- First-mover advantage in novel mechanism blood coagulation treatments
- Expert management team with deep hemophilia and rare disease expertise
- Multiple clinical-stage assets addressing underserved rare bleeding disorders
Bear Case
1 risk
- Above-average volatility (beta 1.9).
Growth
Stable outlook
Advancement of HMB-001 and HMB-002 through clinical development stages
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+73.8% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying COAG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 11, 2026
Reported EPS of -$0.80 vs -$0.73 consensus (-9.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-9.2%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wedbush · Aug 12, 2026
vs Industry
How COAG stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related